Earnings

Quince Therapeutics Q2 EPS $(12.31) Beats $(26.32) Estimate

Aug 14, 2026 · 08:19 AM ET· updated 55m ago

Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(12.31) per share which beat the analyst consensus estimate of $(26.32) by 53.21 percent. This is a 81.9 percent increase over losses of $(68.00) per share

Why It Matters

Quince lost less money than people expected, which is good news. When a company that's losing money loses *less* than predicted, that shows things might be getting better.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

QNCX31.61

-0.80 (-2.47%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.